Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 May;31(5):818–820. doi: 10.1128/aac.31.5.818

Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum.

R N Jones, A L Barry
PMCID: PMC174842  PMID: 3606081

Abstract

Eighty-seven organisms were tested against ceftriaxone, cefotaxime, desacetylcefotaxime, and the combination of cefotaxime and desacetylcefotaxime (1:1 ratio) in broth containing 0, 25, or 50% human serum. In the presence of human serum, ceftriaxone MICs were four- to eightfold higher than those obtained in broth, changing 98% of Staphylococcus aureus strains from the susceptible to the moderately susceptible category and 53% of selected gram-negative strains to a more resistant category. The MICs of cefotaxime, desacetylcefotaxime, and cefotaxime plus desacetylcefotaxime were not adversely affected by human serum; in fact, the bactericidal activity was slightly improved.

Full text

PDF
818

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakker-Woudenberg I. A., van den Berg J. C., Vree T. B., Baars A. M., Michel M. F. Relevance of serum protein binding of cefoxitin and cefazolin to their activities against Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother. 1985 Nov;28(5):654–659. doi: 10.1128/aac.28.5.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barry A. L., Jones R. N., Packer R. R. Antistaphylococcal activity of ceforanide and cefonicid in the presence of human serum. Antimicrob Agents Chemother. 1986 Jan;29(1):147–149. doi: 10.1128/aac.29.1.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. George R. H. The influence of protein binding on the antistaphylococcal activity of antibiotics. J Antimicrob Chemother. 1986 Apr;17(4):539–540. doi: 10.1093/jac/17.4.539. [DOI] [PubMed] [Google Scholar]
  4. Gerding D. N., Peterson L. R. Serum protein binding and extravascular distribution of antimicrobials. J Antimicrob Chemother. 1985 Feb;15(2):136–138. doi: 10.1093/jac/15.2.136. [DOI] [PubMed] [Google Scholar]
  5. Jones R. N., Packer R. R. Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins. Antimicrob Agents Chemother. 1982 Dec;22(6):985–989. doi: 10.1128/aac.22.6.985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kunin C. M. Clinical pharmacology of the new penicillins. 1. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin Pharmacol Ther. 1966 Mar-Apr;7(2):166–179. doi: 10.1002/cpt196672166. [DOI] [PubMed] [Google Scholar]
  7. Labro M. T., Babin-Chevaye C., Hakim J. Effects of cefotaxime and cefodizime on human granulocyte functions in vitro. J Antimicrob Chemother. 1986 Aug;18(2):233–237. doi: 10.1093/jac/18.2.233. [DOI] [PubMed] [Google Scholar]
  8. Lode H., Kemmerich B., Koeppe P., Belmega D., Jendroschek H. Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin Ther. 1980;3(Spec Issue):80–88. [PubMed] [Google Scholar]
  9. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Richards D. M., Heel R. C., Brogden R. N., Speight T. M., Avery G. S. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984 Jun;27(6):469–527. doi: 10.2165/00003495-198427060-00001. [DOI] [PubMed] [Google Scholar]
  11. Sahm D. F., Baker C. N., Jones R. N., Thornsberry C. Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis. J Clin Microbiol. 1984 Sep;20(3):561–567. doi: 10.1128/jcm.20.3.561-567.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Stoeckel K., McNamara P. J., Brandt R., Plozza-Nottebrock H., Ziegler W. H. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther. 1981 May;29(5):650–657. doi: 10.1038/clpt.1981.90. [DOI] [PubMed] [Google Scholar]
  13. Tompsett R., Shultz S., McDermott W. The Relation of Protein Binding to the Pharmacology and Antibacterial Activity of Penicillins X, G, Dihydro F, and K. J Bacteriol. 1947 May;53(5):581–595. doi: 10.1128/jb.53.5.581-595.1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Trang J. M., Jacobs R. F., Kearns G. L., Brown A. L., Wells T. G., Underwood F. L., Kluza R. B. Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis. Antimicrob Agents Chemother. 1985 Dec;28(6):791–795. doi: 10.1128/aac.28.6.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wise R. Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. I. J Antimicrob Chemother. 1983 Jul;12(1):1–18. doi: 10.1093/jac/12.1.1. [DOI] [PubMed] [Google Scholar]
  16. Wise R. Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. II. Studies in man. J Antimicrob Chemother. 1983 Aug;12(2):105–118. doi: 10.1093/jac/12.2.105. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES